small molecule

DEXYCU KIT

DEXAMETHASONE

Loss of exclusivityJune 2039latest FDA-listed patent expiry

CompanyEyePoint Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	DEXYCU KIT
Active ingredient	DEXAMETHASONE
Strength	9%
Dosage form	SUSPENSION
Route	INTRAOCULAR
Modality	Small molecule
FDA approval	February 2018
Marketing status	RX

Listed patents

Patent	Expires	Type
11097061	June 2039	product
10022502	June 2034	use U-2340
10028965	May 2034	use U-2340
10159683	May 2034	product
10799642	May 2032	product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.